Sellas Life Sciences Group Inc
NASDAQ:SLS
Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
Pipeline Progress: SELLAS advanced late-stage clinical programs, including initiating a pivotal Phase III trial for GPS in AML and progressing a Phase I/II basket trial with Merck's Keytruda.
Positive NPS Data: Final Phase IIb data for NPS (NeuVax) in triple negative breast cancer showed a significant reduction in relapse or death risk and robust safety, supporting further FDA engagement.
Financial Strength: Raised approximately $22 million in equity and added $6.6 million from a litigation settlement, eliminating all company debt and supporting ongoing operations.
Cash Runway: Management reiterated that cash and equivalents are sufficient to fund operations through at least March 2019.
Regulatory and Partnerships: Active discussions with the FDA and potential partners for NPS, with an important FDA meeting set for December.
Expense Trends: Increased R&D expenses due to clinical trial activity, but overall cost control and expense guidance will be updated with Q4 results.
